Glomerulonephritic Syndrome – A Complete Patient Guide
Overview
Glomerulonephritic syndrome (GNS) is a group of clinical findings that result from inflammation of the glomeruli – the tiny filtering units in the kidneys. When the glomeruli become damaged, they leak blood and protein into the urine and are less able to remove waste and excess fluid from the bloodstream.
GNS can occur at any age, but the epidemiology varies by underlying cause:
- Children: Post‑infectious (post‑streptococcal) glomerulonephritis is the most common cause, affecting roughly 1–2 per 100,000 children per year in the United States.[1] CDC, 2022
- Adults: IgA nephropathy, membranous nephropathy, and lupus‑related nephritis are leading etiologies, with a combined prevalence of ~150–200 cases per million adults worldwide.[2] WHO Kidney Disease Report, 2021
Overall, glomerulonephritis accounts for about 10 % of end‑stage renal disease (ESRD) cases in the United States.[3] NIH, 2023
Symptoms
The hallmark of glomerulonephritic syndrome is the classic “triad” of:
- Hematuria – pink or cola‑colored urine due to red blood cells leaking into the urinary tract.
- Proteinuria – foamy urine caused by excess protein loss; amounts range from mild (<1 g/day) to nephrotic‑level (>3.5 g/day).
- Edema – swelling, especially around the eyes, ankles, and feet, due to fluid retention.
Additional symptoms may develop as the disease progresses or based on the specific underlying cause:
Renal‑related signs
- Reduced urine output (oliguria) or complete lack of urine (anuria).
- Hypertension (high blood pressure) – present in up to 70 % of adult patients.[4] Cleveland Clinic, 2022
- Flank or abdominal pain (less common, may indicate kidney capsule stretch).
Systemic manifestations
- Fever, chills, or malaise – especially in post‑infectious forms.
- Skin rash or joint pain – can accompany lupus‑related glomerulonephritis.
- Fatigue and weakness due to anemia from chronic kidney disease.
Causes and Risk Factors
Glomerulonephritic syndrome is not a single disease; it is a manifestation of many distinct disorders that share a common pathway of glomerular inflammation. The main categories are:
Infection‑related
- Post‑streptococcal glomerulonephritis (PSGN) – follows throat or skin infection with Group A Streptococcus; latency 1‑3 weeks.
- Viral infections – hepatitis B, C, HIV, and COVID‑19 have been linked to immune complex deposition.
Immune‑mediated
- IgA nephropathy (Berger disease) – the most common primary glomerulonephritis worldwide; involves IgA immune complexes.
- Membranous nephropathy – often associated with antibodies against phospholipase A2 receptor (PLA2R).
- Lupus nephritis – part of systemic lupus erythematosus (SLE); immune complex deposition.
- ANCA‑associated vasculitis – includes granulomatosis with polyangiitis (GPA) and microscopic polyangiitis.
Other causes
- Rapidly progressive glomerulonephritis (RPGN) – a fulminant form that can evolve to ESRD within weeks.
- Hereditary diseases (e.g., Alport syndrome).
- Drug‑induced (e.g., NSAIDs, penicillamine, gold salts).
Risk factors
- Age > 30 years for most adult forms (IgA, membranous, lupus).
- Genetic predisposition – certain HLA types increase susceptibility.
- Chronic infections or repeated streptococcal infections.
- Autoimmune disorders (SLE, rheumatoid arthritis).
- Exposure to nephrotoxic drugs or toxins (e.g., heavy metals).
- Smoking – associated with higher risk of IgA nephropathy progression.
Diagnosis
Diagnosing GNS involves confirming glomerular inflammation, quantifying kidney function, and identifying the underlying cause.
Clinical evaluation
- Detailed history (recent infections, medication use, family history, systemic symptoms).
- Physical exam focusing on blood pressure, edema, and signs of systemic disease (rash, joint swelling).
Laboratory tests
- Urinalysis – looks for red blood cell (RBC) casts, dysmorphic RBCs, and protein level.
- Quantitative proteinuria – 24‑hour urine collection or spot protein/creatinine ratio.
- Serum creatinine & eGFR – assess renal function.
- Complement levels (C3, C4) – low C3 suggests post‑infectious or lupus nephritis.
- Serologic panels – ANA, anti‑dsDNA (lupus), anti‑PLA2R (membranous), ANCA, anti‑GBM antibodies.
- Infectious work‑up – throat/skin cultures, anti‑streptolysin O (ASO) titers, hepatitis serologies.
Imaging
- Renal ultrasound – evaluates kidney size, obstruction, and cortical echogenicity.
- CT or MRI only if structural abnormalities are suspected.
Kidney biopsy
Considered the gold standard when the cause is unclear or when rapid progression is possible. Light microscopy, immunofluorescence, and electron microscopy together reveal:
- Pattern of immune‑complex deposition (granular vs linear).
- Extent of crescent formation (RPGN).
- Specific markers (IgA, IgG, C3, PLA2R, etc.).
Guidelines from the KDIGO (Kidney Disease: Improving Global Outcomes) recommend biopsy for most adults with unexplained hematuria + proteinuria >0.5 g/day or rapidly declining eGFR.[5] KDIGO 2023
Treatment Options
Treatment is twofold: manage the acute inflammatory process and protect remaining kidney function. Strategies differ according to the underlying disease.
General measures for all patients
- Control blood pressure – target <140/90 mm Hg; <130/80 mm Hg if proteinuria >1 g/day.[6] AHA/ACC 2023
- Reduce proteinuria – ACE inhibitors (e.g., lisinopril) or ARBs (e.g., losartan) are first‑line.
- Dietary sodium restriction (<2 g/day) to limit edema and hypertension.
- Avoid nephrotoxic agents (NSAIDs, contrast dyes) and adjust dosages of renally cleared drugs.
Cause‑specific therapies
Post‑infectious glomerulonephritis
- Supportive care – fluid balance, BP control.
- Antibiotics only to eradicate residual streptococcal infection; they do not alter renal outcomes.
- Corticosteroids are not routinely recommended but may be used in severe cases with rapidly falling eGFR.
IgA nephropathy
- Optimized BP control (ACEi/ARB).
- Fish‑oil supplements (omega‑3) have modest benefit in proteinuria reduction.
- In high‑risk patients (≥1 g/day proteinuria, eGFR <50 ml/min/1.73 m²), consider corticosteroids (e.g., oral prednisone 0.8–1 mg/kg) or mycophenolate mofetil.
- Newer agents: N‑acetylcysteine and complement inhibitors (e.g., narsoplimab) are under investigation.
Membranous nephropathy
- Conservative therapy (ACEi/ARB, statins, salt restriction).
- Immunosuppression for persistent nephrotic‑range proteinuria >4 g/day after 6 months: rituximab (375 mg/m² weekly × 4) or cyclophosphamide + steroids (Ponticelli regimen).
- Anti‑PLA2R antibody titers guide treatment intensity and monitor response.
Lupus nephritis
- Induction therapy: high‑dose IV methylprednisolone (0.5–1 g/day × 3 days) followed by oral prednisone.
- Immunosuppressive agents – mycophenolate mofetil (MMF) or cyclophosphamide, depending on class of lupus nephritis.
- Maintenance: lower‑dose prednisone + MMF or azathioprine.
- Hydroxychloroquine is recommended for all SLE patients to reduce flares.
ANCA‑associated vasculitis
- Rapid induction with high‑dose steroids + either rituximab (375 mg/m² weekly × 4) or cyclophosphamide.
- Plasma exchange may be added for severe pulmonary‑renal syndrome.
- Maintenance with rituximab or azathioprine for 12–24 months.
Adjunctive therapies
- Diuretics (loop diuretics) for edema resistant to ACEi/ARB.
- Statins for dyslipidemia, especially in nephrotic syndrome.
- Vaccinations – influenza, pneumococcal, hepatitis B (important for immunosuppressed patients).
Living with Glomerulonephritic Syndrome
Long‑term management focuses on preserving kidney function, preventing complications, and maintaining quality of life.
Daily self‑care
- Blood pressure monitoring: Check at least twice weekly; keep a log for your clinician.
- Fluid balance: Weigh yourself each morning; a sudden gain >2 kg may indicate fluid retention.
- Diet:
- Low‑sodium (<2 g/day) and moderate protein (0.8 g/kg body weight) diet.
- Limit potassium and phosphorus if labs are high (consult a renal dietitian).
- Medication adherence: Take ACEi/ARB at the same time each day; set phone reminders.
- Physical activity: Aim for 150 min/week of moderate aerobic exercise (walking, swimming) unless contraindicated by severe hypertension or cardiac disease.
Monitoring schedule
| Test | Frequency | Purpose |
|---|---|---|
| Serum creatinine/eGFR | Every 3–6 months (more often if unstable) | Assess kidney function |
| Urine protein/creatinine ratio | Every 3 months | Track proteinuria trends |
| Blood pressure | At home daily; clinic visit every 1–2 months | Guide antihypertensive therapy |
| Complement levels/autoantibodies | Every 6–12 months or when disease flares | Detect relapse or response to therapy |
Psychosocial support
- Join a kidney disease support group (national and local chapters).
- Consider counseling for anxiety or depression – chronic illness can affect mood.
- Discuss work accommodations early; many patients can continue employment with flexible schedules.
Prevention
Because many forms of GNS are triggered by infections or autoimmune activity, absolute prevention is impossible, but risk can be lowered:
- Prompt treatment of streptococcal throat or skin infections; complete the full antibiotic course.
- Maintain good oral hygiene – periodontal disease has been linked to IgA nephropathy exacerbations.
- Vaccinate against hepatitis B, influenza, and COVID‑19.
- Smoking cessation – reduces immune activation and slows progression.
- Control comorbidities (diabetes, hypertension, hyperlipidemia) that accelerate kidney damage.
- Avoid unnecessary NSAIDs and over‑the‑counter herbal supplements with nephrotoxic potential.
Complications
If left untreated or inadequately controlled, glomerulonephritic syndrome can lead to serious sequelae:
- Chronic kidney disease (CKD) progression – up to 30 % of adults develop ESRD within 10 years of diagnosis.[7] NIH, 2023
- Hypertensive emergencies – malignant hypertension can cause retinal hemorrhage, stroke, or cardiac failure.
- Nephrotic‑syndrome complications – hyperlipidemia, thromboembolism (especially renal vein thrombosis), and severe hypoalbuminemia.
- Infections – immunosuppressive therapy raises susceptibility to bacterial, viral, and fungal infections.
- Cardiovascular disease – CKD and proteinuria independently increase risk of myocardial infarction and heart failure.
- Electrolyte disturbances – hyperkalemia, metabolic acidosis, and phosphate retention.
When to Seek Emergency Care
Call 911 or go to the nearest emergency department immediately if you notice any of the following:
- Sudden, severe swelling of the face, lips, or tongue (possible allergic reaction to medication).
- Rapid rise in blood pressure >180/120 mm Hg with headache, vision changes, or chest pain.
- Marked decrease in urine output (<100 mL in 24 hours) or complete absence of urine.
- Sudden onset of gross (dark red or cola‑colored) hematuria accompanied by flank pain.
- Shortness of breath, swelling of the whole body, or rapid weight gain (>5 kg in 48 hours) suggesting fluid overload.
- Fever >38.5 °C (101.3 °F) with chills in a patient on immunosuppressive therapy – risk of sepsis.
**References**
- CDC. “Post‑streptococcal Glomerulonephritis.” 2022.
- World Health Organization. “Global Kidney Health Atlas.” 2021.
- National Institutes of Health. “Kidney Disease Statistics.” 2023.
- Cleveland Clinic. “Hypertension in Kidney Disease.” Updated 2022.
- Kidney Disease: Improving Global Outcomes (KDIGO). “Clinical Practice Guideline for Glomerulonephritis.” 2023.
- American Heart Association / American College of Cardiology. “2023 Hypertension Guideline.”
- NIH. “Outcomes of Glomerulonephritis.” 2023.